TWI615400B - 5'-經取代核苷化合物 - Google Patents
5'-經取代核苷化合物 Download PDFInfo
- Publication number
- TWI615400B TWI615400B TW105112724A TW105112724A TWI615400B TW I615400 B TWI615400 B TW I615400B TW 105112724 A TW105112724 A TW 105112724A TW 105112724 A TW105112724 A TW 105112724A TW I615400 B TWI615400 B TW I615400B
- Authority
- TW
- Taiwan
- Prior art keywords
- mixture
- mmol
- pyrimidin
- compound
- cancer
- Prior art date
Links
- 0 CC1**CC1 Chemical compound CC1**CC1 0.000 description 3
- JAPMJSVZDUYFKL-UHFFFAOYSA-N C1C2C1CCC2 Chemical compound C1C2C1CCC2 JAPMJSVZDUYFKL-UHFFFAOYSA-N 0.000 description 1
- XAZKFISIRYLAEE-UHFFFAOYSA-N CC1CC(C)CC1 Chemical compound CC1CC(C)CC1 XAZKFISIRYLAEE-UHFFFAOYSA-N 0.000 description 1
- MOLJRYADXUOLOM-HDMKZQKVSA-N C[C@]([C@H](CC1)O[C@H]1[n](cc1)c2c1c(N)ncn2)(c(cc1)ccc1Cl)O Chemical compound C[C@]([C@H](CC1)O[C@H]1[n](cc1)c2c1c(N)ncn2)(c(cc1)ccc1Cl)O MOLJRYADXUOLOM-HDMKZQKVSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/14—Pyrrolo-pyrimidine radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Peptides Or Proteins (AREA)
- Saccharide Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15382225 | 2015-05-04 | ||
??15382225.9 | 2015-05-04 |
Publications (2)
Publication Number | Publication Date |
---|---|
TW201712022A TW201712022A (zh) | 2017-04-01 |
TWI615400B true TWI615400B (zh) | 2018-02-21 |
Family
ID=53177322
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW105112724A TWI615400B (zh) | 2015-05-04 | 2016-04-22 | 5'-經取代核苷化合物 |
Country Status (25)
Country | Link |
---|---|
US (1) | US9840532B2 (es) |
EP (1) | EP3292128A1 (es) |
JP (2) | JP6181889B1 (es) |
KR (1) | KR20170132871A (es) |
CN (1) | CN107580602A (es) |
AR (1) | AR104326A1 (es) |
AU (1) | AU2016258485A1 (es) |
BR (1) | BR112017020336A2 (es) |
CA (1) | CA2981097A1 (es) |
CL (1) | CL2017002637A1 (es) |
CO (1) | CO2017010727A2 (es) |
CR (1) | CR20170443A (es) |
DO (1) | DOP2017000255A (es) |
EA (1) | EA201792169A1 (es) |
EC (1) | ECSP17072987A (es) |
HK (1) | HK1244007A1 (es) |
IL (1) | IL254409A0 (es) |
MA (1) | MA42036A (es) |
MX (1) | MX2017014001A (es) |
PE (1) | PE20180231A1 (es) |
PH (1) | PH12017502002A1 (es) |
SG (1) | SG11201708345XA (es) |
TN (1) | TN2017000459A1 (es) |
TW (1) | TWI615400B (es) |
WO (1) | WO2016178870A1 (es) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20170119705A (ko) * | 2015-02-24 | 2017-10-27 | 화이자 인코포레이티드 | 항암제로서 유용한 치환된 뉴클레오시드 유도체 |
WO2018139181A1 (ja) * | 2017-01-27 | 2018-08-02 | 国立大学法人 宮崎大学 | 抗がん剤、抗がん剤のスクリーニング方法、がんに対する有効性判定キット及びがんに対する有効性判定方法 |
WO2018152548A1 (en) | 2017-02-20 | 2018-08-23 | Prelude Therapeutics, Incorporated | Selective inhibitors of protein arginine methyltransferase 5 (prmt5) |
WO2018152501A1 (en) | 2017-02-20 | 2018-08-23 | Prelude Therapeutics, Incorporated | Selective inhibitors of protein arginine methyltransferase 5 (prmt5) |
WO2018160855A1 (en) | 2017-03-01 | 2018-09-07 | Prelude Therapeutics, Incorporated | Selective inhibitors of protein arginine methyltransferase 5 (prmt5) |
EP3665179B1 (en) * | 2017-08-09 | 2021-06-09 | Prelude Therapeutics, Incorporated | Selective inhibitors of protein arginine methyltransferase 5 (prmt5) |
WO2019084470A1 (en) | 2017-10-26 | 2019-05-02 | Prelude Therapeutics, Incorporated | SELECTIVE INHIBITORS OF THE PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5) |
IL274936B2 (en) | 2017-12-13 | 2023-09-01 | Lupin Ltd | Transmuted heterocyclic bicyclic compounds as prmt5 inhibitors |
KR20200132916A (ko) | 2018-03-14 | 2020-11-25 | 프렐루드 테라퓨틱스, 인코포레이티드 | 단백질 아르기닌 메틸트랜스퍼라제 5(prmt5)의 선택적 억제제 |
US10711007B2 (en) | 2018-03-14 | 2020-07-14 | Prelude Therapeutics Incorporated | Selective inhibitors of protein arginine methyltransferase 5 (PRMT5) |
JP7337539B2 (ja) * | 2018-06-21 | 2023-09-04 | メディヴィル・アクチエボラーグ | 白血病療法のための塩基修飾シチジンヌクレオチド |
WO2020033285A1 (en) * | 2018-08-07 | 2020-02-13 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
MX2021009796A (es) * | 2019-02-13 | 2021-09-08 | Prelude Therapeutics Inc | Inhibidores selectivos de la proteina arginina metiltransferasa 5 (prmt5). |
RS64972B1 (sr) | 2019-06-10 | 2024-01-31 | Lupin Ltd | Inhibitori prmt5 |
GEP20247638B (en) | 2019-10-22 | 2024-07-10 | Lupin Ltd | Pharmaceutical combination of prmt5 inhibitors |
EP4069698A1 (en) | 2019-12-03 | 2022-10-12 | Lupin Limited | Substituted nucleoside analogs as prmt5 inhibitors |
GB202117230D0 (en) | 2021-11-29 | 2022-01-12 | Argonaut Therapeutics Ltd | Peptide vaccine |
GB202203588D0 (en) | 2022-03-15 | 2022-04-27 | Argonaut Therapeutics Ltd | Cancer diagnostic |
CN116211869B (zh) * | 2022-12-07 | 2023-08-01 | 浙江省肿瘤医院 | 含dna损伤修复抑制剂的药物混合物及混合方法、用途 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1384834A (zh) * | 1999-08-27 | 2002-12-11 | Icn药品公司 | 吡咯并[2,3-d]嘧啶核苷类似物 |
WO2007069923A1 (en) * | 2005-12-15 | 2007-06-21 | Industrial Research Limited | Deazapurine analogs of 1'-aza-l-nucleosides |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9044432B2 (en) | 2009-12-22 | 2015-06-02 | Ohio State Innovation Foundation | Compositions and methods for cancer detection and treatment |
US9416154B2 (en) * | 2011-07-13 | 2016-08-16 | Merck Sharp & Dohme Corp. | 5′-substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases |
WO2014100730A1 (en) | 2012-12-21 | 2014-06-26 | Epizyme, Inc. | Prmt5 inhibitors containing a dihydro- or tetrahydroisoquinoline and uses thereof |
US20150344457A1 (en) | 2012-12-21 | 2015-12-03 | Epizyme, Inc. | Methods of inhibiting prmt5 |
JP2016505597A (ja) | 2012-12-21 | 2016-02-25 | エピザイム,インコーポレイティド | Prmt5阻害剤およびその使用 |
US9365555B2 (en) * | 2012-12-21 | 2016-06-14 | Epizyme, Inc. | PRMT5 inhibitors and uses thereof |
US9908887B2 (en) | 2012-12-21 | 2018-03-06 | Epizyme, Inc. | PRMT5 inhibitors and uses thereof |
US8993555B2 (en) | 2012-12-21 | 2015-03-31 | Epizyme, Inc. | PRMT5 inhibitors and uses thereof |
KR20170119705A (ko) * | 2015-02-24 | 2017-10-27 | 화이자 인코포레이티드 | 항암제로서 유용한 치환된 뉴클레오시드 유도체 |
-
2016
- 2016-04-20 AR ARP160101081A patent/AR104326A1/es unknown
- 2016-04-22 TW TW105112724A patent/TWI615400B/zh not_active IP Right Cessation
- 2016-04-27 CA CA2981097A patent/CA2981097A1/en not_active Abandoned
- 2016-04-27 KR KR1020177031713A patent/KR20170132871A/ko active Search and Examination
- 2016-04-27 CR CR20170443A patent/CR20170443A/es unknown
- 2016-04-27 WO PCT/US2016/029475 patent/WO2016178870A1/en active Application Filing
- 2016-04-27 US US15/139,370 patent/US9840532B2/en not_active Expired - Fee Related
- 2016-04-27 EP EP16720676.2A patent/EP3292128A1/en not_active Withdrawn
- 2016-04-27 SG SG11201708345XA patent/SG11201708345XA/en unknown
- 2016-04-27 TN TNP/2017/000459A patent/TN2017000459A1/en unknown
- 2016-04-27 JP JP2016575652A patent/JP6181889B1/ja not_active Expired - Fee Related
- 2016-04-27 AU AU2016258485A patent/AU2016258485A1/en not_active Abandoned
- 2016-04-27 PE PE2017002330A patent/PE20180231A1/es not_active Application Discontinuation
- 2016-04-27 EA EA201792169A patent/EA201792169A1/ru unknown
- 2016-04-27 BR BR112017020336-7A patent/BR112017020336A2/pt not_active Application Discontinuation
- 2016-04-27 MA MA042036A patent/MA42036A/fr unknown
- 2016-04-27 MX MX2017014001A patent/MX2017014001A/es unknown
- 2016-04-27 CN CN201680025080.3A patent/CN107580602A/zh active Pending
-
2017
- 2017-02-15 JP JP2017025494A patent/JP2017125029A/ja active Pending
- 2017-09-11 IL IL254409A patent/IL254409A0/en unknown
- 2017-10-17 CL CL2017002637A patent/CL2017002637A1/es unknown
- 2017-10-20 CO CONC2017/0010727A patent/CO2017010727A2/es unknown
- 2017-10-30 DO DO2017000255A patent/DOP2017000255A/es unknown
- 2017-11-01 EC ECIEPI201772987A patent/ECSP17072987A/es unknown
- 2017-11-03 PH PH12017502002A patent/PH12017502002A1/en unknown
-
2018
- 2018-03-15 HK HK18103599.9A patent/HK1244007A1/zh unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1384834A (zh) * | 1999-08-27 | 2002-12-11 | Icn药品公司 | 吡咯并[2,3-d]嘧啶核苷类似物 |
WO2007069923A1 (en) * | 2005-12-15 | 2007-06-21 | Industrial Research Limited | Deazapurine analogs of 1'-aza-l-nucleosides |
Also Published As
Publication number | Publication date |
---|---|
CO2017010727A2 (es) | 2018-01-31 |
JP2017525667A (ja) | 2017-09-07 |
CL2017002637A1 (es) | 2018-04-20 |
JP2017125029A (ja) | 2017-07-20 |
CA2981097A1 (en) | 2016-11-10 |
MA42036A (fr) | 2018-03-14 |
TW201712022A (zh) | 2017-04-01 |
PH12017502002A1 (en) | 2018-03-26 |
MX2017014001A (es) | 2018-03-16 |
EP3292128A1 (en) | 2018-03-14 |
TN2017000459A1 (en) | 2019-04-12 |
EA201792169A1 (ru) | 2018-03-30 |
KR20170132871A (ko) | 2017-12-04 |
HK1244007A1 (zh) | 2018-07-27 |
PE20180231A1 (es) | 2018-01-31 |
IL254409A0 (en) | 2017-11-30 |
JP6181889B1 (ja) | 2017-08-16 |
DOP2017000255A (es) | 2018-01-15 |
CN107580602A (zh) | 2018-01-12 |
AU2016258485A1 (en) | 2017-10-12 |
CR20170443A (es) | 2017-11-07 |
BR112017020336A2 (pt) | 2019-05-14 |
ECSP17072987A (es) | 2018-02-28 |
SG11201708345XA (en) | 2017-11-29 |
WO2016178870A1 (en) | 2016-11-10 |
AR104326A1 (es) | 2017-07-12 |
US20160326208A1 (en) | 2016-11-10 |
US9840532B2 (en) | 2017-12-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI615400B (zh) | 5'-經取代核苷化合物 | |
JP7206314B2 (ja) | Jak及びpi3k阻害剤併用によるb細胞悪性腫瘍の処置 | |
EP3423451B1 (en) | Inhibitors of wdr5 protein-protein binding | |
KR102533599B1 (ko) | 단백질 티로신 포스파타제 억제제 및 이의 사용 방법 | |
CA3056754A1 (en) | Macrocyclic compounds as ros1 kinase inhibitors | |
JP2022071072A (ja) | (s)-7-(1-アクリロイルピペリジン-4-イル)-2-(4-フェノキシフェニル)-4,5,6,7-テトラ-ヒドロピラゾロ[1,5-a]ピリミジン-3-カルボキサミドの結晶形、その調製、及びその使用 | |
EP3814341B1 (en) | Erbb receptor inhibitors | |
CN112341457A (zh) | Kras突变蛋白抑制剂 | |
JP2009504621A (ja) | 糖尿病の処置のためのヘテロアリールカルバモイルベンゼン誘導体 | |
TW201202222A (en) | Inhibitors of HCV NS5A | |
CN108409820A (zh) | 作为hcv rna复制抑制剂的4′-叠氮基,3′-氟取代的核苷衍生物 | |
JP2019507179A (ja) | Wdr5タンパク質−タンパク質結合の阻害剤 | |
US20230279004A1 (en) | Solid forms, salts, and processes of preparation of a cdk2 inhibitor | |
TW201733587A (zh) | 1,3,4-噻二唑化合物及其在治療癌症中之用途 | |
CN118666832A (zh) | 作为smarca2/brm atp酶抑制剂的脲化合物和组合物 | |
US20220185815A1 (en) | Pyrrolopyrazole derivative | |
WO2011068187A1 (ja) | キナゾリン誘導体 | |
US11013728B2 (en) | Cyclin-dependent kinase 8 and/or 19 inhibitor | |
JP6257835B2 (ja) | 新規なトリアゾロピリミジノン又はトリアゾロピリジノン誘導体、及びこれらの用途 | |
EP4013756B1 (en) | Mll1 inhibitors and anti-cancer agents | |
BR112017018312B1 (pt) | Sais de inibidor de pi3k, composições que as compreende, seu uso, processos para seu preparo e método de inibição de uma atividade de uma quinase pi3k |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Annulment or lapse of patent due to non-payment of fees |